PURPOSE: To review the @entity16 associated with extracranial carotid artery stenting and to preliminarily assess techniques used to manage these complications. METHODS: Between April 1994 and August 2000, 450 @entity1 (270 @entity1 ; mean age 70.2 years, range 27-89) had stents implanted to treat 472 cervical carotid artery stenoses. Over half (257, 57%) of the @entity1 were symptomatic. A variety of stents were implanted percutaneously after predilation of the lesion; a third of the @entity1 received glycoprotein IIb/ IIIa inhibitors intraprocedurally in addition to a standard oral antiplatelet regimen ( @entity117 and @entity1396 or @entity1397 ). Occurrence and management of @entity16 within the 30-day periprocedural period were reviewed. RESULTS: There were 14 (3.1%) transient @entity63 attacks (TIAs), 10 (2.2%) minor @entity64 , and 3 (0.7%) major @entity64 . Among 6 (1.3%) procedure-related @entity204 , 4 had neurological causes. The @entity64 and @entity204 rate was 4.2% (n = 19). All the TIAs, 4 of which occurred between 1 and 14 days poststenting, were treated medically, as were the minor @entity64 , 3 of which occurred >24 hours after stenting. Only 2 minor @entity64 @entity1 had mild residual @entity71 . Intra-arterial thrombolytic therapy was administered in 5 cases (2 major @entity64 survivors and 3 @entity1 who suffered a neurologically-related @entity204 ); occlusions were identified in the proximal middle cerebral artery (MCA) in 3 and the distal @entity9623 in 2. Angiographic improvement was noted in 4 (80%), but only the 2 (40%) with @entity2500 did well clinically. CONCLUSIONS: @entity16 following carotid artery stenting are inevitable. The occurrence of minor @entity64 >24 hours following stenting may indicate a possible late @entity887 , which warrants investigation. Likewise, the marginal efficacy of intra-arterial thrombolytic therapy demonstrates an @entity887 and underscores the need for effective distal protection.

Management of XXXX of carotid artery stenting.

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes', 'stroke', 'total stroke'] @entity1396 :: ('MESH:D013988', 'Chemical') :: ['ticlopidine'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity2500 :: ('MESH:D020244', 'Disease') :: ['distal MCA occlusions'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity16 :: ('MESH:D009422', 'Disease') :: ['Neurological complications', 'neurological complications'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity71 :: ('MESH:D001289', 'Disease') :: ['upper extremity motor deficits'] @entity887 :: ('MESH:D004617', 'Disease') :: ['inability to lyse embolic plaque', 'embolic phenomenon'] @entity9623 :: ('CHEBI:34342', 'Chemical') :: ['MCA'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths', 'death']
@entity16 :: (MESH:D009422,Disease) :: ['neurological complications']
